不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
成人异基因移植后体内 T 细胞去除后的腺病毒血症：低淋巴细胞计数与无法控制的病毒血症和致死性结局相关
英文原题：Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes.
查看英文原题
Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
成人移植受者中腺病毒血症的发生率以及筛查在预防腺病毒病中的作用尚未明确。2017年1月至2020年5月期间，采用体内T细胞清除进行了262例异基因移植。59例患者发现腺病毒血症，100天累积发生率为10%，一年累积发生率为23%（95% CI 20-26%）。脐血移植与更高的病毒血症发生率相关（p = .04）。未发现其他患者、供者或移植特征可预测病毒血症。在47例患者（80%）中，病毒血症始终远低于200,000 copies/mL并自行消退。12例患者出现高水平病毒血症。抗病毒治疗以及部分病例的过继细胞治疗往往无效，仅2例存活。初次检测到腺病毒血症时淋巴细胞计数低是疾病失控的最佳预测指标。
展开英文摘要原文
The incidence of adenovirus viremia and the role of screening in preventing adenovirus disease in adult transplant recipients are not well defined. Between January 2017 and May 2020, 262 allogeneic transplants were performed using in vivo T-cell depletion. Adenovirus viremia was found in 59 patients for a cumulative incidence of 10% by one hundred days and 23% (95% CI 20-26%) by one year. There was a higher incidence of viremia associated with cord blood transplant ( p = .
04). No other patient, donor or transplant characteristics were identified that predicted for viremia. In 47 patients (80%), viremia remained well below 200,000 copies/mL and resolved. Twelve patients developed high level viremia. Treatment with antivirals and in some cases adoptive cell therapy, was often ineffective and only two survived. Low lymphocyte count at initial detection of adenovirus viremia was the best predictor of uncontrolled disease.
论文信息
- 作者
- Chaekal OK、Soave R、Chen Z、Shore T、Mayer S、Phillips A、Mei Hsu J、Gomez-Arteaga A
- 第一作者单位
- Department of Healthcare Policy and Research, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.United States
- 通讯作者单位
- Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.United States
- 期刊
- Leukemia & lymphoma2022 Feb
- 原文标识
- PubMed 34643477 · DOI 10.1080/10428194.2021.1978088